NVIDIA BioNeMo Unveils Evo 2: A Groundbreaking Biomolecular AI Model

NVIDIA BioNeMo has launched Evo 2, a cutting-edge biomolecular AI model, which marks a significant advancement in the field of genomic data analysis. According to NVIDIA, this model is the largest publicly available AI tool for genomic research, developed in collaboration with the Arc Institute and Stanford University on the NVIDIA DGX Cloud platform.

Revolutionizing Genomic Research

Evo 2 is trained on an extensive dataset comprising nearly 9 trillion nucleotides, the fundamental components of DNA and RNA. This model is poised to transform biomolecular research applications, enabling the prediction of protein structures and functions from genetic sequences, discovering new molecules for healthcare, and assessing the impact of gene mutations on their functions.

Patrick Hsu, cofounder of Arc Institute and an assistant professor at the University of California, Berkeley, emphasized the model’s potential, stating, “Evo 2 represents a major milestone for generative genomics.” He further noted the model’s capacity to advance solutions in healthcare and environmental science.

Enhanced Access and Capabilities

Available globally on the NVIDIA BioNeMo platform, Evo 2 can be utilized as an NVIDIA NIM microservice, facilitating secure and efficient AI deployment. Researchers can fine-tune the model using proprietary datasets, leveraging the open-source NVIDIA BioNeMo Framework, which offers accelerated computing tools for biomolecular studies.

Brian Hie, assistant professor at Stanford University, highlighted the model’s impact on biological design, describing it as a tool that makes the design of complex biological systems more accessible and efficient.

Applications in Diverse Scientific Fields

Evo 2’s capabilities extend across various scientific domains, including healthcare, agricultural biotechnology, and materials science. Trained on a diverse range of species, the model can process genetic sequences up to 1 million tokens in length, offering insights into the connections between genetic code and cellular functions.

In healthcare, Evo 2 aids in identifying gene variants linked to diseases and designing targeted molecular treatments. For instance, in studies involving the BRCA1 gene associated with breast cancer, the model demonstrated a 90% accuracy rate in predicting the effects of previously unknown mutations.

Agriculturally, Evo 2 can address global food challenges by providing insights into plant biology, aiding in the development of climate-resilient and nutrient-rich crops. Additionally, it holds potential in designing biofuels and engineering proteins for industrial applications.

Dave Burke, Arc’s chief technology officer, likened the deployment of Evo 2 to launching a powerful new telescope, opening vast possibilities for scientific discovery.

Image source: Shutterstock